Effect of ranolazine on the course of ischemic heart disease after percutaneous coronary intervention
Optimization of antiischemic therapy is necessary in many patients with stable forms of coronary heart disease after or during revascularization. From the standpoint of current guidelines, the addition of second-line drugs, in particular ranolazine, to beta-blockers and/or calcium antagonists is con...
Saved in:
Main Authors: | О.А. Yepanchintseva, O.J. Zharinov, І.V. Shklianka |
---|---|
Format: | Article |
Language: | English |
Published: |
TOV Chetverta Khvylia
2020-12-01
|
Series: | Кардіохірургія та інтервенційна кардіологія |
Subjects: | |
Online Access: | http://www.csic.com.ua/images/pdf/2020/4-2020/effect-ranolazine-course-ischemic-heart-disease-after-percutaneous-coronary-intervention.pdf |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Prognostic value of remnant-like particle cholesterol in ischemic heart failure patients following percutaneous coronary intervention
by: Xin Huang, et al.
Published: (2025-12-01) -
Research progress on coronary slow flow or no-reflow of coronary heart disease undergoing percutaneous coronary intervention surgery
by: Mengdi Wang, et al.
Published: (2025-01-01) -
Clinical characteristics and usage of statins in patients with stable ischemic heart disease referred for angiography or coronary artery bypass grafting
by: I.V. Shklianka, et al.
Published: (2017-12-01) -
Association of Time in Target Range of Resting Heart Rate With Adverse Clinical Outcomes in Patients With Acute Coronary Syndromes After Percutaneous Coronary Intervention
by: Jianmei Zheng, et al.
Published: (2025-01-01) -
Long-term cardiovascular outcomes after percutaneous coronary intervention in patients with systemic sclerosis
by: Kazutoshi Hirose, et al.
Published: (2025-04-01)